Skip to content

Dietary Intervention for NSCLC Patients Treated With ICI

Non Small Cell Lung Cancer

This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Signed, informed consent
* Age 18 years or older
* Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI
* Ability to eat solid foods

Exclusion Criteria:

* Severe dietary allergies (e.g. shellfish, nuts, seafood)
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Study Location

Centre hospitalier de l'Université de Montréal (CHUM)
Centre hospitalier de l'Université de Montréal (CHUM)
Montréal, Quebec
Canada

Contact Study Team

Backup Contact

Arielle Elkrief, MD

[email protected]
514-890-8000
Primary Contact

Wiam Belkaid, PhD

[email protected]
514-836-3273
Study Sponsored By
Centre hospitalier de l'Université de Montréal (CHUM)
Participants Required
More Information
Study ID: NCT05805319